Fibronostics is pleased to announce that new data on LIVERFASt™, its non-invasive blood-based diagnostic test for liver disease, will be presented at the EASL Congress 2026, taking place in Barcelona, Spain from 27–30 May 2026.

Two abstracts have been accepted for poster presentation within the MASLD: Diagnostics and Non-Invasive Assessment session, highlighting continued advancements in the clinical evaluation of metabolic dysfunction-associated steatotic liver disease (MASLD) and steatohepatitis (MASH).

The accepted abstracts will explore:

• The role of LIVERFASt in identifying patients at risk of advanced fibrosis within MASLD populations, including those with type 2 diabetes (T2D)
• The evolving role of non-invasive tests in monitoring disease dynamics in patients undergoing emerging therapies

These presentations reflect Fibronostics’ ongoing commitment to advancing accessible, non-invasive approaches to liver disease assessment, supporting earlier detection and more informed clinical decision-making.